Polycystic Ovary Syndrome and the Metabolic Syndrome Long-Term Risks

January 2008 in “ Humana Press eBooks ”

Eva Dahlgren, Per Olof Janson

Polycystic Ovary Syndrome PCOS metabolic syndrome hyperandrogenism hyperinsulinism insulin resistance metformin ovulation induction endometrial cancer

Studysummary This article reviews the relationship between polycystic ovary syndrome and various health issues but provides no new clinical findings; it emphasizes the need for continued research and lifestyle interventions.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document reviewed the long-term risks associated with Polycystic Ovary Syndrome (PCOS) and its connection to the metabolic syndrome. It highlighted the correlation between hyperandrogenism and hyperinsulinism in PCOS, suggesting that women with PCOS were at an increased risk for cardiovascular diseases and type 2 diabetes due to insulin resistance. Studies indicated that women with PCOS often experienced menstrual irregularities and infertility, which could be managed with treatments like metformin and ovulation induction. Additionally, the document discussed the potential increased risk of endometrial cancer in women with PCOS, emphasizing the importance of monitoring and managing metabolic and reproductive health in these patients.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Finasteride Versus Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism

39 citations , August 2004 in “International journal of gynaecology and obstetrics”

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

research Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?

418 citations , June 2003 in “Endocrine Reviews”

This review discusses the relationship between polycystic ovary syndrome and cardiovascular risk, noting a possible adverse impact on risk profiles and subclinical atherosclerosis but no clear increase in premenopausal cardiovascular events; it presents no new clinical results.

research Topical Eflornithine: Efficacy in Reducing Unwanted Facial Hair Growth in Women

115 citations , January 2001 in “American journal of clinical dermatology”

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

research Usefulness of a 12-Month Treatment with Finasteride in Idiopathic and Polycystic Ovary Syndrome-Associated Hirsutism

4 citations , January 1999 in “PubMed”

Gonadotrophin-Releasing Hormone Agonist Therapy for Hirsutism Is as Effective as High Dose Cyproterone Acetate but Results in a Longer Remission

research Gonadotrophin-Releasing Hormone Agonist Therapy for Hirsutism Is as Effective as High Dose Cyproterone Acetate but Results in a Longer Remission

49 citations , April 1997 in “Human reproduction”

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.